Which hedge funds own BBIO? BRIDGEBIO PHARMA INC, Q2 2026 13F holders
82 tracked hedge funds disclosed a position in BBIO (BRIDGEBIO PHARMA INC) in their Q2 2026 13F filings, worth $6.0bn in total. The largest holder by portfolio weight is Kohlberg Kravis Roberts & Co. L.P. at 17.3% of its book. 21 opened a new position this quarter: Ishara Investments LP, Ares Systematic Credit Ltd, Moore Capital Management, LP, Catalyst Funds Management Pty Ltd. 19 exited: Eagle Health Investments LP, Diadema Partners LP, Sofinnova Investments, Inc..
- 82
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 21
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 19
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $303m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $223m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $6.0bn
- Combined value Sum of the holders' reported positions in the security.
- 6.6%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Eagle Health Investments LP | 4.2% | $19.8m |
| Diadema Partners LP | 2.6% | $6.3m |
| Sofinnova Investments, Inc. | 1.5% | $30.4m |
| Deep Track Capital, LP | 1.3% | $62.5m |
| Cinctive Capital Management LP | 0.7% | $10.8m |
| Affinity Asset Advisors, LLC | 0.7% | $11.1m |
| Camden Asset Management L P | 0.4% | $12.9m |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 0.4% | $27.1m |
| Atika Capital Management LLC | 0.4% | $2.6m |
| Artia Global Partners LP | 0.3% | $1.5m |
| Atom Investors LP | 0.2% | $2.6m |
| Voloridge Investment Management, LLC | 0.1% | $31.7m |
| Prelude Capital Management, LLC | 0.08% | $1.0m |
| SummitTX Capital, L.P. | 0.07% | $2.3m |
| AlphaGrep UK Ltd | 0.07% | $224k |
| Fox Run Management, L.L.C. | 0.04% | $212k |
| Alphadyne Asset Management LP | 0.01% | $75.3k |
| Elequin Capital, LP | 0.0% | $24.0k |
| Caption Management, LLC | 0.0% | $32.0k |
Ownership over time
Who discovered BBIO first? Beta
The run: Q4 2022 → Q4 2025, +904%
| Diameter Capital Partners LP high conviction | Q1 2022 | 4.7% | +23.5 pts |
| Laurion Capital Management LP high conviction | Q1 2023 | 0.5% | +16.7 pts |
| Cormorant Asset Management, LP high conviction | Q1 2023 | 0.7% | +10.8 pts |
| Frazier Life Sciences Management, L.P. high conviction | Q1 2023 | – | +8.4 pts |
| Aristeia Capital, L.L.C. | Q1 2022 | 1.8% | +5.8 pts |
| Context Capital Management, LLC | Q1 2022 | 1.0% | +5.3 pts |
| Sphera Funds Management Ltd. | Q1 2023 | – | +3.3 pts |
| Ikarian Capital, LLC high conviction | Q1 2023 | – | +3.0 pts |
| Contrarian Capital Management, L.L.C. | Q3 2022 | 0.9% | +0.9 pts |
| Highbridge Capital Management LLC | Q1 2022 | 0.8% | +0.7 pts |
| Hhlr Advisors, Ltd. | Q1 2023 | 0.8% | −0.2 pts |
| Mirabella Financial Services LLP | Q1 2023 | – | – |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.